[通过克隆形成试验进行的体外II-III期研究：丝裂霉素C与α-干扰素的联合作用]

[In vitro phase II-III study by clonogenic assay: the combined effects of mitomycin C with alpha-interferon].

作者信息

Hirabayashi N, Nosoh Y, Toge T, Yoshinaka K, Yamaguchi M, Nishiyama M, Niimoto M, Hattori T

出版信息

Gan To Kagaku Ryoho. 1986 Mar;13(3 Pt 1):531-5.

Abstract

Using the human tumor clonogenic assay technique, the combined effects of mitomycin C (MMC) with alpha-interferon (HLBI) were surveyed in comparison with 33 fresh human tumor specimens. Tumors in this study were 16 gastric cancers, five breast cancers, four liposarcomas, three colon cancers, two gall bladder cancers, two esophageal cancers, and one hepatoma. When the survival fraction observed in drug combination was smaller than the multiplication of each survival fraction observed in each drug alone, the combined effects were considered to be synergistic. Twenty-two of 33 tumors (gastric cancer 11/16, breast cancer 5/5, liposarcoma 2/4, colon cancer 1/3, gall bladder cancer 2/2, esophageal cancer 1/2, and hepatoma 0/1) formed adequate colony numbers for the evaluation of combined drug effects. Synergistic effects were observed in seven tumors (three gastric cancers, one breast cancer, one gall bladder cancer, one liposarcoma and one esophageal cancer), although three tumors (one gastric cancer, one gall bladder cancer, and one colon cancer) exhibited antagonistic effects.

摘要

采用人肿瘤克隆形成试验技术，以33例新鲜人肿瘤标本为对照，研究了丝裂霉素C（MMC）与α-干扰素（HLBI）的联合效应。本研究中的肿瘤包括16例胃癌、5例乳腺癌、4例脂肪肉瘤、3例结肠癌、2例胆囊癌、2例食管癌和1例肝癌。当联合用药时观察到的存活分数小于每种药物单独使用时观察到的存活分数的乘积时，联合效应被认为是协同的。33例肿瘤中有22例（胃癌11/16、乳腺癌5/5、脂肪肉瘤2/4、结肠癌1/3、胆囊癌2/2、食管癌1/2、肝癌0/1）形成了足够数量的集落用于联合药物效应评估。在7例肿瘤（3例胃癌、1例乳腺癌、1例胆囊癌、1例脂肪肉瘤和1例食管癌）中观察到协同效应，不过有3例肿瘤（1例胃癌、1例胆囊癌和1例结肠癌）表现出拮抗效应。